PHOENIX BIOTECH ACQUISITION CORP.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)CER-1236 in Patients With Acute Myeloid Leukemia (AML)
Phase 1
Recruiting
- Conditions
- AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- CERo Therapeutics Holdings, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06834282
- Locations
- 🇺🇸
Sarah Cannon Research Insitute, Nashville, Tennessee, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
News
CERo Therapeutics Advances Novel CER-T Cell Therapy for AML with Invivoscribe Diagnostic Support
CERo Therapeutics has initiated a Phase 1 clinical trial for CER-1236, a novel Chimeric Engulfment Receptor T-cell (CER-T) therapy targeting acute myeloid leukemia patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML.